Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-16), Sunho Biologics's share price is HK$6.39. Sunho Biologics's Book Value per Share for the quarter that ended in Jun. 2025 was HK$3.36. Hence, Sunho Biologics's PB Ratio of today is 1.90.
The historical rank and industry rank for Sunho Biologics's PB Ratio or its related term are showing as below:
HKSE:02898'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 1.9
Current: 1.9
During the past 3 years, Sunho Biologics's highest PB Ratio was 1.90. The lowest was 0.00. And the median was 0.00.
HKSE:02898's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.88
vs HKSE:02898: 1.90
During the past 12 months, Sunho Biologics's average Book Value Per Share Growth Rate was -10.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Sunho Biologics PB Ratio Related Terms
Sunho Biologics PB Ratio Historical Data
* Premium members only.
The historical data trend for Sunho Biologics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02898 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Sunho Biologics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunho Biologics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sunho Biologics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Sunho Biologics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Sunho Biologics's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Sunho Biologics (HKSE:02898) has a PB Ratio of 1.90 as of Aug. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sunho Biologics and its competitors.
Is Sunho Biologics' PB Ratio too high?
Sunho Biologics' current PB Ratio is 1.90. The Biotechnology industry median PB Ratio is 2.88. Sunho Biologics' value of 1.90 is 34% below this industry median. Overall, Sunho Biologics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Sunho Biologics' PB Ratio compare to VRTX and REGN?
Sunho Biologics' PB Ratio of 1.90 can be compared against companies in the Biotechnology industry. The industry median PB Ratio is 2.88. Sunho Biologics' value of 1.90 is 34% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.88, based on 1,220 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunho Biologics's current PB Ratio of 1.90 is 34% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sunho Biologics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunho Biologics's current PB Ratio is 1.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunho Biologics stock overvalued right now?
Sunho Biologics (HKSE:02898) has a current PB Ratio of 1.90. The current PB Ratio is 1.90 and 34% below the Biotechnology industry median of 2.88. Sunho Biologics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sunho Biologics (HKSE:02898), the current PB Ratio is 1.90 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.
11GF Score
Get the complete analysis for HKSE:02898
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02898 has been successfully added to your 
